Patents by Inventor Sylvia Grünewald
Sylvia Grünewald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220153745Abstract: This invention relates to novel substituted 5-(1-benzothiophen-2-yl) pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives of formula (I) wherein R1 is hydrogen, chloro, methyl or methoxy, R2 is hydrogen or methoxy, with the proviso that at least one of R1 and R2 is other than hydrogen, G1 represents chloro, (C1-C4)-alkyl, (C1-C4)-alkoxycarbonyl, 5-membered aza-heteroaryl, or the group —CH2—OR3, —CH2—NR4R5 or —C(=0)-NR4R6, and G2 represents chloro, cyano, (C1-C4)-alkyl, or the group —CR8AR8B—OH, —CH2—NR9R10, —C(=0)—NR11R12 or —CH2—OR15, having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.Type: ApplicationFiled: November 1, 2021Publication date: May 19, 2022Inventors: Dirk BROHM, Melanie HEROULT, Marie-Pierre COLLIN, Walter HÜBSCH, Mario LOBELL, Klemens LUSTIG, Sylvia GRÜNEWALD, Ulf BÖMER, Verena VÖHRINGER
-
Publication number: 20210369724Abstract: The present invention relates to combinations of: component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2) as defined herein, or a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof; and component B: one or more ATR kinase inhibitor(s) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof; and, optionally, component C: one or more further pharmaceutical agent(s); and, optionally, in which either or both of components A and B in any of the above-mentioned combinations are in the form of a pharmaceutical composition which is ready for use to be administered simultaneously, concurrently, separately or sequentially. The components may be administered independently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route.Type: ApplicationFiled: October 9, 2019Publication date: December 2, 2021Applicant: Bayer AktiengesellschaftInventors: Antje Margret WENGNER, Gerhard SIEMEISTER, Sylvia GRÜNEWALD, Bernard HAENDLER, Ningshu LIU
-
Publication number: 20190031773Abstract: The present invention is related to an antagonist of PYCR1 for the treatment and/or prevention of a neoplastic disease.Type: ApplicationFiled: May 23, 2018Publication date: January 31, 2019Inventors: Sylvia GRÜNEWALD, Michael STECKEL, Manfred HUSEMANN, Hanna MEYER, Weiping HAN, Zhaobing DING
-
Publication number: 20190016724Abstract: This invention relates to novel substituted 5-(1-benzothiophen-2-yl) pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives of formula (I) wherein R1 is hydrogen, chloro, methyl or methoxy, R2 is hydrogen or methoxy, with the proviso that at least one of R1 and R2 is other than hydrogen, G1 represents chloro, (C1-C4)-alkyl, (C1-C4)-alkoxycarbonyl, 5-membered aza-heteroaryl, or the group —CH2—OR3, —CH2—NR4R5 or —C(?O)-NR4R6, and G2 represents chloro, cyano, (C1-C4)-alkyl, or the group —CR8AR8B—OH, —CH2—NR9R10, —C(?O)—NR11R12 or —CH2—OR15, having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.Type: ApplicationFiled: February 20, 2018Publication date: January 17, 2019Inventors: Dirk BROHM, Melanie HEROULT, Marie-Pierre COLLIN, Walter HÜBSCH, Mario LOBELL, Klemens LUSTIG, Sylvia GRÜNEWALD, Ulf BÖMER, Verena VÖHRINGER
-
Patent number: 9598416Abstract: This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-fJ[1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.Type: GrantFiled: December 11, 2012Date of Patent: March 21, 2017Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Marie-Pierre Collin, Dirk Brohm, Mélanie Héroult, Mario Lobell, Walter Hübsch, Klemens Lustig, Sylvia Grünewald, Ulf Bömer, Verena Vöhringer, Niels Lindner
-
Patent number: 9475815Abstract: This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.Type: GrantFiled: February 20, 2013Date of Patent: October 25, 2016Assignee: BAYER INTELLETUAL PROPERTY GMBHInventors: Mario Lobell, Walter Hübsch, Hartmut Schirok, Mélanie Héroult, Dirk Brohm, Marie-Pierre Collin, Sylvia Grünewald, Klemens Lustig, Ulf Bömer, Verena Voehringer, Niels Lindner
-
Patent number: 9394309Abstract: The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumor disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: January 23, 2013Date of Patent: July 19, 2016Assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbHInventors: Frank Süβmeier, Mario Lobell, Sylvia Grünewald, Michael Härter, Bernd Buchmann, Joachim Telser, Hannah Jöriβen, Melanie Heroult, Antje Kahnert, Klemens Lustig, Niels Lindner
-
Patent number: 9206184Abstract: This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.Type: GrantFiled: December 14, 2012Date of Patent: December 8, 2015Assignee: BAYER INTELLECTUAL PROPERTY GmbHInventors: Dirk Brohm, Melanie Heroult, Marie-Pierre Collin, Walter Hübsch, Mario Lobell, Klemens Lustig, Sylvia Grünewald, Ulf Bömer
-
Publication number: 20150080371Abstract: This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-fJ[1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.Type: ApplicationFiled: December 11, 2012Publication date: March 19, 2015Inventors: Marie-Pierre Collin, Dirk Brohm, Melanie Heroult, Mario Lobell, Walter Hübsch, Klemens Lustig, Sylvia Grünewald, Ulf Bömer, Verena Vöhringer, Niels Lindner
-
Publication number: 20150031676Abstract: This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.Type: ApplicationFiled: February 20, 2013Publication date: January 29, 2015Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Mario Lobell, Walter Hübsch, Hartmut Schirok, Mélanie Héroult, Dirk Brohm, Marie-Pierre Collin, Sylvia Grünewald, Klemens Lustig, Ulf Bömer, Verena Vöhringer, Niels Lindner
-
Publication number: 20150005288Abstract: The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumour disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: January 22, 2013Publication date: January 1, 2015Applicants: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbHInventors: Frank Süssmeier, Mario Lobell, Sylvia Grünewald, Michael Härter, Bernd Buchmann, Joachim Telser, Hannah Jörissen, Melanie Heroult, Antje Kahnert, Klemens Lustig, Niels Lindner
-
Publication number: 20140336173Abstract: This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives of formula (I) wherein R1 is hydrogen, chloro, methyl or methoxy, R2 is hydrogen or methoxy, with the proviso that at least one of R1 and R2 is other than hydrogen, G1 represents chloro, (C1-C4)-alkyl, (C1-C4)-alkoxycarbonyl, 5-membered aza-heteroaryl, or the group —CH2—OR3, —CH2—NR4R5 or —C(?O)—NR4R6, and G2 represents chloro, cyano, (C1-C4)-alkyl, or the group —CR8AR8B—OH, —CH2—NR2R10, —C(?O)—NR11R12 or —CH2—OR15, having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.Type: ApplicationFiled: December 10, 2012Publication date: November 13, 2014Inventors: Dirk Brohm, Melanie Heroult, Marie-Pierre Collin, Walter Hübsch, Mario Lobell, Klemens Lustig, Sylvia Grünewald, Ulf Bömer, Verena Vöhringer
-
Patent number: 8349619Abstract: The invention relates to various methods of detecting and analyzing protein interactions in a cell, which methods involve the appearance of a specific protein interaction being converted to a permanent detection signal by means of providing, in a manner dependent on said protein interaction, a recombinase activity or protease activity.Type: GrantFiled: May 1, 2009Date of Patent: January 8, 2013Assignee: Sygnis Bioscience GmbH & Co. KGInventors: Moritz Rossner, Rico Laage, Klaus-Armin Nave, Sylvia Gruenewald
-
Publication number: 20090298089Abstract: The invention relates to various methods of detecting and analyzing protein interactions in a cell, which methods involve the appearance of a specific protein interaction being converted to a permanent detection signal by means of providing, in a manner dependent on said protein interaction, a recombinase activity or protease activity.Type: ApplicationFiled: May 1, 2009Publication date: December 3, 2009Inventors: Moritz Rossner, Rico Laage, Klaus-Armin Nave, Sylvia Gruenewald
-
Patent number: 7585635Abstract: Described are various methods of detecting and analyzing protein interactions in a cell. The specific protein interaction is detected by a permanent signal generated by a recombinase activity or protease activity that depends on the protein interaction.Type: GrantFiled: March 13, 2003Date of Patent: September 8, 2009Assignee: Sygnis Bioscience GmbH & Co. KGInventors: Moritz Rossner, Rico Laage, Klaus-Armin Nave, Sylvia Gruenewald
-
Publication number: 20050084864Abstract: The invention relates to a method of detecting and analyzing protein interactions in a cell, which comprises the steps: d) provision of the activity of at least one enzyme from the group consisting of recombinases and proteases in the cell as a result of a protein interaction, e) continual generation of an active reporter protein in the cell in question as a result of the enzymic activity of step a) for a period of time which exceeds the duration of the protein interaction of step a), f) generation of a detection signal by the reporter proteins generated in b). The invention furthermore relates to reverse embodiments of the method above of detecting and analyzing protein interactions in a cell, with, as a result of the induced dissociation of a defined interaction between proteins, the activity of at least one enzyme from the group consisting of recombinases and proteases being provided in the cell and converted to a permanent detection signal of said cell.Type: ApplicationFiled: March 13, 2003Publication date: April 21, 2005Applicant: AXARON BIOSCIENCE AGInventors: Moritz Rossner, Rico Laage, Klaus-Armin Nave, Sylvia Gruenewald